Madrigal Pharmaceuticals, Inc. GAAP EPS of -$1.90 beats by $1.51, revenue of $212.8M beats by $50.63M

15 hours ago 1

Madrigal Pharmaceuticals, Inc. press release (NASDAQ:MDGL): Q2 GAAP EPS of -$1.90 beats by $1.51.
Revenue of $212.8M (+1357.5% Y/Y) beats by $50.63M.
Total revenues: Second-quarter 2025 net revenues were $212.8 million, compared to $14.6 million in the comparable prior year period. The increase is due to increased demand for Rezdiffra.

Recommended For You